Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Scientific Indications for Priorities of SARS-CoV-2 Vaccination in Patients with Cancer

Scientific Indications for Priorities of SARS-CoV-2 Vaccination in Patients with Cancer
ESMO-CoV-2-Vaccine-Webinar-Series-Webinar-Banners_16-February-1000x250px
Start date
16 Feb 2021
End date
16 Feb 2021

The ESMO Webinar Series is freely available to all healthcare professionals working in Oncology. 

The programme is designed to offer expert opinion exchange and provide some considerations on key economic, ethical and societal aspects of prioritising the SARS-CoV-2 vaccination, as well as the balance between personal and societal freedoms, and special issues in vulnerable patient groups.

Chair

Florian Scotté

Speakers

Christina Ruhlmann, Emanuela Romano, Giovanni Boniolo

Programme

  • Welcome and introduction, Dr. Florian Scotté, Gustave Roussy Cancer Campus, Interdisciplinary Cancer Course Department, Villejuif, France
  • Scientific Considerations in Prioritising Population Groups for SARS-CoV-2 Vaccination - Where are Cancer Patients Positioned?, Dr. Christina H. Ruhlmann, Department of Oncology, Odense University Hospital, Odense, Denmark
  • Considerations in Prioritising Subgroups Within the Population of Patients with Cancer, Dr. Emanuela Romano, Department of Oncology, INSERM U932, Institut Curie, Paris, France
  • Obligatory vs Elective Vaccination Strategy in High-Risk Populations - The Ethical and Scientific Issues, Prof. Giovanni Boniolo, Department of Neuroscience and Rehabilitation, University of Ferrara, Ferrara, Italy
  • Q&A
  • Closing Remarks, Dr. Florian Scotté, Gustave Roussy Cancer Campus, Interdisciplinary Cancer Course Department, Villejuif, France

Learning objectives: 

  • To understand different considerations important for SARS-CoV-2 vaccination prioritisation from the aspects of general population vs patients with cancer
  • To understand different considerations in prioritising subgroups of patients with cancer
  • To understand different ethical challenges posed by SARS-CoV-2 vaccination

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.